A groundbreaking study reveals HPV vaccination can nearly eliminate cancer deaths, yet uptake remains alarmingly low in Germany.

A recent study published in The Lancet highlights the life-saving potential of the HPV vaccine, showing it can drastically reduce cancer-related deaths. Conducted in England, the research found that cervical cancer mortality among vaccinated women aged 20-24 dropped to zero between 2020 and 2024. For women aged 25-29, death rates also plummeted significantly. Since its introduction in 2008, the HPV vaccine has saved an estimated 200 lives in England, according to the study authors.

Human papillomaviruses (HPV) are linked to severe cancers, including cervical, anal, oral, and penile cancers, causing 8,000 cases annually in Germany alone. Of these, 2,000 result in fatalities—1,600 women and 400 men. HPV spreads through skin and mucous membrane contact during vaginal, oral, and anal sex. While most infections resolve naturally, about 10% lead to cancer after a long incubation period of up to 20 years.

The study underscores the importance of early vaccination. Germany’s Standing Committee on Vaccination (Stiko) recommends the HPV vaccine for children aged 9-14, ideally before their first sexual contact. Immunologist Anja Takla from the Robert Koch Institute emphasizes that delayed vaccination reduces its effectiveness. Despite its proven safety and coverage by health insurance, Germany’s vaccination rates remain low—only 55% of 15-year-old girls and 36% of boys are fully vaccinated. Experts warn this is insufficient to achieve herd immunity, which requires at least 80% coverage.

HPV affects both genders, debunking the misconception that it is solely a women’s issue. While women bear the brunt of cervical cancer cases, men are also at risk of HPV-related cancers. Public health experts, including Nobila Ouédraogo from the German Cancer Research Center, stress the need for better education and outreach to families. Scandinavian countries and England have implemented successful strategies like school-based vaccinations and government-issued reminders, which could serve as models for Germany.

Boosting vaccination rates is critical to preventing future suffering. HPV vaccines offer robust protection against the virus’s most dangerous strains, yet Germany lags behind other nations in uptake. Experts call for urgent action to improve accessibility and awareness, ensuring more children receive this life-saving vaccine early. With proactive measures, Germany could significantly reduce HPV-related cancers and deaths, following England’s example of near-zero mortality among vaccinated populations.